Subscribe to the newsletter

Publication — IRIC

A renaissance for YES in cancer.

Most of our understanding regarding the involvement of SRC-family tyrosine kinases in cancer has stemmed from studies focused on the prototypical SRC oncogene. However, emerging research has shed light on the important role of YES signaling in oncogenic transformation, tumor growth, metastatic progression, and resistance to various cancer therapies. Clinical evidence indicates that dysregulated expression or activity of YES is a frequent occurrence in human cancers and is associated with unfavorable outcomes. These findings provide a compelling rationale for specifically targeting YES in certain cancer subtypes. Here, we review the crucial role of YES in cancer and discuss the challenges associated with translating preclinical observations into effective YES-targeted therapies.

Publication date
October 17, 2023
Principal Investigators
Lapouge M, Meloche S
PubMed reference
Oncogene 2023
PubMed ID
Institute for Research in Immunology and Cancer, Montreal, QC, Canada.